Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study.

Affiliation

Department of Experimental and Clinical Medicine, University of Florence, Italy; Research Center Denothe, University of Florence, Italy. Electronic address: [Email]

Abstract

Transjugular Intrahepatic Portosystemic Shunt (TIPS) is a well-established treatment for complications of portal hypertension.

Keywords

Advanced liver disease,Antiviral therapy,Cirrhosis complications,Portal hypertension,

OUR Recent Articles